PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples

BACKGROUND: Despite the utility of antiangiogenic drugs in ovarian cancer, efficacy remains limited due to resistance linked to alternate angiogenic pathways and metastasis. Therefore, we investigated PG545, an anti-angiogenic and anti-metastatic agent which is currently in Phase I clinical trials,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Cancer
Asıl Yazarlar: Winterhoff, Boris, Freyer, Luisa, Hammond, Edward, Giri, Shailendra, Mondal, Susmita, Roy, Debarshi, Teoman, Attila, Mullany, Sally A., Hoffmann, Robert, von Bismarck, Antonia, Chien, Jeremy, Block, Matthew S., Millward, Michael, Bampton, Darryn, Dredge, Keith, Shridhar, Viji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4402130/
https://ncbi.nlm.nih.gov/pubmed/25754234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.02.007
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller